MUTAGENICITY STUDIES OF DL-8280, A NEW ANTIBACTERIAL DRUG
-
- SHIMADA HIROYASU
- Research Institute, Daiichi Seiyaku Co., Ltd.
-
- EBINE YUTAKA
- Research Institute, Daiichi Seiyaku Co., Ltd.
-
- KUROSAWA YUMIKO
- Research Institute, Daiichi Seiyaku Co., Ltd.
-
- ARAUCHI TATSUO
- Research Institute, Daiichi Seiyaku Co., Ltd.
Bibliographic Information
- Other Title
-
- 新合成抗菌剤DL-8280の変異原性に関する検討
Abstract
A new antibacterial drug, DL-8280, was studied for mutagenicity using various in vitro and in vivo short-term tests as follows.(1) To detect primary DNA damage: the rec-assay on B. subtilis, the sister chromatid exchange (SCE) test on Chinese hamster cells and human peripheral blood lymphocytes, and the unscheduled DNA synthesis (UDS) test on human diploid cells.(2) To detect gene mutations: the reverse mutation test (Ames method) on S. typhimurium and E. coli.(3) To detect chromosomal aberrations: in vitro and in vivo cytogenetic assay using human peripheral blood lymphocytes, and mouse micronucleus test.<BR>In the rec-assay, DL-8280 showed the primary DNA damaging effect caused by the antibacterial activity to the tester strains, but no mutagenicity was observed either in the SCE test or in the UDS test. Therefore it was proved that DL-8280 had no primary DNA damaging effect on mammalian cells. In addition, DL-8280 had no mutagenic effects in the reverse mutation test, in the cytogenetic assay and in the micronucleus test.<BR>These results suggest that DL-8280 has no mutagenic potential.
Journal
-
- CHEMOTHERAPY
-
CHEMOTHERAPY 32 (Supplement1), 1162-1170, 1984
Japanese Society of Chemotherapy
- Tweet
Details 詳細情報について
-
- CRID
- 1390001206281160576
-
- NII Article ID
- 130004071811
-
- ISSN
- 18845894
- 00093165
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed